Meanwhile, many new drugs (e.g., BCL-2 inhibitor) could be used in the treatment of AML, which would help to further improve the clinical outcomes of patients with high-level RUNX1-RUNX1T1 (50–52). This evidence concerns the gene RUNX1 and acute myeloid leukemia.